In this Pharmaceutical Executive Video Interview, Panna Sharma, CEO of Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing and emerging therapies for relapsed/refractory lymphoma and solid tumors. I will explain how it is compatible.
Addressing unmet needs with LP-284 for relapsed/refractory lymphoma and solid tumors
Leave a comment
